Fusion Pharmaceuticals Inc.

If you purchased Fusion Pharmaceuticals Inc. securities and would like to join the action, please click "Join This Action" below.

We would handle the action on a contingent fee basis, whereby you would not be responsible for out of pocket payment of our legal fees or expenses.

FUSN STOCK ALERT: HALPER SADEH LLC IS INVESTIGATING WHETHER THE SALE OF FUSION PHARMACEUTICALS INC. IS FAIR TO SHAREHOLDERS

March 19, 2024.

New York, New York—Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Fusion Pharmaceuticals Inc. (NASDAQ: FUSN) to AstraZeneca is fair to Fusion shareholders. Under the terms of the proposed transaction, AstraZeneca would acquire all of Fusion’s outstanding shares for $21.00 per share in cash at closing plus a non-transferable contingent value right of $3.00 per share in cash payable upon the achievement of a specified regulatory milestone.

The investigation concerns whether Fusion and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to, among other things: (1) obtain the best possible consideration for Fusion shareholders; (2) determine whether AstraZeneca is underpaying for Fusion; and (3) disclose all material information necessary for Fusion shareholders to adequately assess and value the merger consideration.

On behalf of Fusion shareholders, Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits. We would handle the action on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Certification

Full Name or Entity*

If Representing an Entity, Position at Entity

Street Address*

Address Line 2

City*

State*

Zip Code*

Country*

Phone*

E-Mail Address*

Number of Shares Currently Owned*

Date Shares Were Acquired*

Average Cost Per Share*

I currently hold, and will continue to hold, at least one share of Fusion Pharmaceuticals Inc. while the matter, if any, is pending.*

By signing and clicking the “submit” button below, I hereby execute the Retainer Agreement and agree to retain Halper Sadeh LLC in the Fusion Pharmaceuticals Inc. shareholder matter on a contingent fee basis pursuant to the terms set forth in the provided Retainer Agreement, which is incorporated by reference herein. Pursuant to the Retainer Agreement, which is effective upon execution by Halper Sadeh LLC, Halper Sadeh LLC will advance all costs and expenses pursuant to the terms set forth in the Retainer Agreement.*

I declare under penalty of perjury, under the laws of the United States of America, that the information entered is accurate.*

Draw Your Signature Below*

Signed pursuant to California Civil Code Section 1633.1, et seq., and the Uniform Electronic Transactions Act as adopted by the various states and territories of the United States.

Date of signing: May 10, 2024

Retainer Agreement